Demand for marine-based drugs will increase through 2036, with marine-derived small molecules at a 40.0% share in 2026 as the leading product segment. The market is expected to reach USD 4.5 billion in 2026 and USD 10.0 billion by 2036, creating an absolute dollar opportunity of USD 5.5 billion.